Navigation Links
MiMedx Announces Record Second Quarter Results
Date:7/31/2013

$

(0.02)Weighted average shares outstanding - basic and diluted95,988,10079,952,54294,599,40677,416,073 

 

MIMEDX GROUP, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETSASSETSJune 30,December 31,20132012(unaudited)Current assets:Cash and cash equivalents

$

4,193,583

$

6,754,485Accounts receivable, net11,761,8747,653,561Inventory, net4,220,2843,022,784Prepaid expenses and other current assets1,351,948657,961Total current assets21,527,68918,088,791Property and equipment, net of accumulated depreciation of $2,517,774 and $2,279,840, respectively2,990,7461,071,625Goodwill4,040,4434,040,443Intangible assets, net of accumulated amortization of $5,378,990 and $4,848,756, respectively11,724,21011,911,749Deposits and other long term assets-70,000Total assets

$

40,283,088

$

35,182,608LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

$

1,837,711

$

1,251,684Accrued compensation2,974,7092,753,237Accrued expenses1,075,916990,697Other current liabilities252,34375,154Total current liabilities6,140,6795,070,772Earn-out liability payable in MiMedx common stock-5,792,330Convertible Senior Secured Promissory Notes, net-4,012,442Other Liabilities1,250,866299,762Total liabilities7,391,54515,175,306Commitments and contingencies Stockholders' equity:Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding--Common stock; $.001 par value;130,000,000shares authorized; 96,356,451 issued and 96,306,451 outstanding for 2013 and 88,423,169 issued and 88,373,169 outstanding for 201296,35588,423Additional paid-in capital104,881,70789,627,601Treasury stock (50,000 shares at cost)(25,000)(25,000)Accumulated deficit(72,061,519)(69,683,722)Total stockholders' equity32,891,54320,007,302Total liabilities and stockholders' equity

$

40,283,088

$

35,182,6
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
2. MiMedx To Exceed High End Of Second Quarter Guidance
3. MiMedx to Ring NASDAQ Stock Market Opening Bell
4. MiMedx to Present at Jefferies 2013 Global Healthcare Conference
5. MiMedx Secures a $3.0 Million Revolving Line of Credit with Bank of America
6. MiMedx Announces Record First Quarter 2013 Results
7. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
8. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
9. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
10. MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference
11. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Asterias Biotherapeutics, ... Company has signed a Notice of Grant Award ... (CIRM), effective October 1, 2014.  The NGA provides ... and the release of additional grant funds pursuant ... award for clinical development of Asterias, product, AST-OPC1. ...
(Date:10/20/2014)... PureTech , a science and technology development ... today the closing of a $55 million growth ... a $120 Billion group of funds. The funding ... forward and to advance new healthcare related products ... really go for the big ideas that can ...
(Date:10/19/2014)... 2014 The Latin American hardware encryption ... Latin America with analysis and forecast of revenue. This ... is expected to reach $2,366.8 million by 2018, at ... Browse through the TOC of the Latin American hardware ... in-depth analysis provided. It also provides a glimpse of ...
(Date:10/19/2014)... The Asian Automatic patient billing report ... and forecast of revenue. The Automatic patient billing market ... million by 2018, at a developing CAGR of 7.2% ... of the Asian Automatic patient billing market, to get ... provides a glimpse of the segmentation of this market ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... , ROCKVILLE, Md. , Aug. 6 ... today the appointment of Richard Douglas , Ph.D. to ... President, Corporate Development at Genzyme Corp.  As a leader of ... numerous acquisitions, licenses, joint ventures and strategic alliances as well ...
... Arizona State University researchers will get support from the ... next generations of lasers and infrared photodetectors. ... for an array of defense and commercial applications. ... Office grant through the defense department,s Multidisciplinary University Research ...
... Vicept Therapeutics, Inc., a privately held specialty biopharmaceutical company, announced ... the Company,s lead product V-101, a topical cream under investigation for ... , , ... crossover clinical trial of 22 patients with rosacea was designed to ...
Cached Biology Technology:NOVAVAX Elects Richard H. Douglas to its Board of Directors 2NOVAVAX Elects Richard H. Douglas to its Board of Directors 3Looking to leap forward on laser and photodetector technologies 2Vicept Therapeutics Announces Positive Clinical Study Results of V-101 for the Treatment of the Erythema of Rosacea 2Vicept Therapeutics Announces Positive Clinical Study Results of V-101 for the Treatment of the Erythema of Rosacea 3
(Date:10/15/2014)... , Oct. 15, 2014 Sandata ... for home and community-based care, today announced it ... implementing Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™) ... is a home health company founded in 1996 ... . The study details ...
(Date:10/15/2014)... of Life, is a non-traditional biophysics textbook and it ... is a journey of discovery into biological systems and ... biological regulation. It is about how our genes make ... the billions of cells in an organism. It quantifies ... principles, which can be found on both large and ...
(Date:10/15/2014)... virus is spreading rapidly and to an unexpected extent. ... the past and the virus shows a new disease ... before. For this reason, the German National Academy of ... and Engineering, and the Union of the German Academies ... the Ebola epidemic today. , In the statement the ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2New book about life as seen from physics 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... 1, 2011 A pathway whereby bacteria communicate with ... Hebrew University of Jerusalem. The discovery has important implications ... bacteria in the body. Bacteria are known to ... of extracellular signalling molecules, said Prof. Sigal Ben-Yehuda of ...
... is known to have cancer-protective properties, and shift work ... production. Shift work has been thought to have important ... increased risk of several cancers including breast, endometrial, prostate, ... study, researchers at Brigham and Women,s Hospital (BWH) found ...
... SEATTLE Twelve graduate students from institutes throughout ... Harold M. Weintraub Graduate Student Award sponsored by the ... Nominations were solicited internationally; the winners were selected on ... their work. , The recipients, all advanced students at ...
Cached Biology News:Shift work may be associated with decreased risk of skin cancer 22011 Harold M. Weintraub Graduate Student Award recipients announced 22011 Harold M. Weintraub Graduate Student Award recipients announced 3
Antibody specific for trimethyl-Lys27 of histone H3. Mouse monoclonal. Antigen: Synthetic peptide derived from histone H3, trimethylated at lysine 27...
DL-Dithiothreitol (Clelands Reagent) ,PROTEASE FREE!! ,Molecular Biology Grade ,PRODUCT MUST SHIP NEXT DAY DURING HOT SUMMER MONTHS. ,C 4 H 10 O 2 S 2 ,Molecular Weight: 154.25 ,CAS RN: [27565-...
DTT 50 l...
...
Biology Products: